



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, August 18, 2011
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Beth Johnson, R.Ph.
Kort DeLost, R.Ph.
Lisa Hunt, R.Ph.
Julia Ozbolt, M.D.

Bernadette Kiraly, M.D.
Karen Gunning, PharmD.
Brandon Jennings, PharmD.

Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, R.Ph.
 Robyn Seely, PharmD.
 Joe Cramer, Medicaid Medical Director

Richard Sorenson, R.N.
 Bobbi Hansen, CPhT

University of Utah Drug Information Center Staff Present:

Gary Oderda, PharmD.

Melissa Archer, PharmD.

Other Individuals Present:

Charissa Anne, J&J
 Brooks Hubbard, Boelinger Ingelheim

Sabrina Aery, BMS
 Courtney Waye, UofU

Meeting conducted by: Karen Gunning PharmD., Co-Chairperson.

- 1 Review and Approval of Minutes: Kort DeLost moved to approve the minutes. List Hunt seconded the motion. The motion was approved unanimously by Beth Johnson, Kort DeLost, Karen Gunning, Lisa Hunt, Brandon Jennings, and Julia Ozbolt.
- 2 Housekeeping: Lisa Hunt initiated introductions for and of new members.
- 3 Election of new Chairperson: Ellie Brownstein, M.D. volunteered for nomination via email. Karen Gunning asked if a Co-Chairperson was necessary, per Lisa Hunt one Chairperson is ok as written in rules. Lisa Hunt nominated Ellie Brownstein as P&T Chairperson for remainder of 2011 and 2012, Kort DeLost seconded the nomination, and nomination was approved unanimously by Beth Johnson, Kort DeLost, Karen Gunning, Lisa Hunt, Brandon Jennings, and Julia Ozbolt.
- 4 DUR Board Update: Robyn Seely addressed the Committee. In August, the DUR Board discussed Chronic Myeloid Leukemia, and determined to keep Gleeev available without PA, take Tasigna off PA, and a new drug Sprycel made available without PA. Next month the DUR Board will be discussing Hepatitis C.
- 5 P&T Updates: Lisa Hunt reported that Medicaid is moving forward with the contracting process for a new POS system. A new PDL has been posted online as of

August 1, 2011 with two new specific classes added (Enzymes and Acne treatment medications). Brandon Jennings asked about posting NDC specific PDLs on the Medicaid website, specifically he is having to call regarding smoking cessation drugs each time they are filled. Lisa Hunt responded that we will make sure the NDC specific list will be posted under “Specific NDC List.” Karen Gunning also suggested posting an NDC specific OTC list.

- 6 Melissa Archer from the University of Utah presented research on topical and vaginal antifungal agents.

Karen Gunning recommended looking at topical antifungal agents first and their various dosage forms, and she described the normal discussion/decision process for new committee members.

Topical antifungals: Bernadette Kiraly expressed that a shampoo option is important to include. She also stated that powder dosage forms are easy options for children and elderly. Kort DeLost suggested a combination product may have cost advantages.

Bernadette Kiraly asked about the effectiveness and cost of Ciclopirox. It was determined to be both inexpensive and ineffective. Karen Dunning suggested that the most effective of the dosage forms available (lacquer) does not fit into this category being discussed.

The question was posed towards the DUR Board as to whether or not the Penlac (lacquer) is covered. Although it is currently not covered it could become available with a brand name PA. Julie Ozbolt agreed that a shampoo dosage form is necessary.

Kort DeLost made a motion that four dosage forms be available; a shampoo (Ketoconazole), a solution, a cream (Clotrimazole) and Nystatin powder. Bernadette Kiraly seconded the motion. The motion was approved unanimously by Beth Johnson, Kort DeLost, Karen Gunning, Lisa Hunt, Brandon Jennings, Julia Ozbolt, and Bernadette Kiraly.

Vaginal antifungals: Kort DeLost asked if any of the efficacy studies recommend one product over another. Melissa Archer stated that the results were attached to materials provided. Brandon Jennings stated that there appeared to be no difference in the study results provided.

Brandon Jennings made a motion that one product be selected based off utilization data, Julie Ozbolt seconded the motion. The motion was approved unanimously by Beth Johnson, Kort DeLost, Karen Gunning, Lisa Hunt, Brandon Jennings, Julia Ozbolt, and Bernadette Kiraly.

Karen Gunning asked if there was anyone present from the public that wanted to comment thus far. None replied.

- 7 Melissa Archer from the University of Utah presented research on oral non-absorbable antifungal agents.

Bernadette Kraily asked about evidence supporting pediatric use of oral non-

absorbable antifungals. No separate studies were provided; the results provided appear to include all age ranges.

Karen Gunning asked if there was anyone present from the public that wanted to comment thus far. None replied.

Bernadette Kraily suggested Nystatin, to keep the same across topical and oral. She also acknowledged that there appears to be no difference between the Mycelex Troche (Clotrimazole) and Nystatin. Kort DeLost commented that diabetic patients could have some problems with Nystatin giving its high sucrose content and suggested use of the Mycelex Troche (Clotrimazole) for these instances. Karen Gunning suggested the route (swish and swallow or spit out) could make a difference. Bernadette Kraily stated that primarily oral agents (such as these) are swish and spit, however patients with dysphasia will tend to swallow.

Bernadette Kraily made a motion that there appears to be no difference in the efficacy and safety of products, recommends covering Nystatin and excluding coverage of Miconazole. Brandon Jennings seconded the motion. The motion was approved unanimously by Beth Johnson, Kort DeLost, Karen Gunning, Lisa Hunt, Brandon Jennings, Julia Ozbolt, and Bernadette Kiraly.

- 8 P&T agenda for coming months was discussed. Lisa Hunt asked if it was helpful for the committee to see other states PDLs to make determinations. Gary Oderda commented that his staff is essentially caught up on all reviews for the next P&T meeting and asked when the committee likes to receive the materials. Lisa Hunt stated that the state would like to receive all materials in the last week of the month (2 weeks prior to scheduled meetings). Other Committee members agree that a minimum of 2 weeks is best for their review.

Next Meeting Set for Thursday, September 15, 2011

Meeting Adjourned.

Minutes prepared by Bobbi Hansen